Posted by dancingstar on January 5, 2005, at 17:01:25
In reply to Re: You might want to give that a second thought...., posted by dancingstar on January 5, 2005, at 2:34:43
This is information presented by Wyeth. You will notice that it refers to "short-term" studies and doesn't indicate the length of those studies nor any other details about these studies; so basically this is simply data that they were required by law to report. This should help anyone that reads it come to their own conclusions about their healthcare. It is my opinion that the that the withdrawal symptoms are higher than is indicated here:
It is an excerpt from the following link:
http://www.wyeth.com/news/Pressed_and_Released/pr12_05_2004_16_03_36.asp"About Venlafaxine in the United States
"In the United States, venlafaxine is marketed as EFFEXOR® (venlafaxine HCl) and EFFEXOR XR® (venlafaxine HCl sustained release). EFFEXOR XR is indicated for the treatment of patients with major depressive disorder, generalized anxiety, and social anxiety disorder. EFFEXOR/EFFEXOR XR is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs). Both adult and pediatric patients taking antidepressants can experience worsening of their depression and/or the emergence of suicidality. Patients should be observed closely for clinical worsening and suicidality, especially at the beginning of drug therapy, or at the time of increases or decreases in dose."Anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania have been reported in patients taking antidepressants. Discontinuation or modification of therapy should be considered when symptoms are severe, abrupt in onset, or not part of presenting symptoms.
"Treatment with venlafaxine is associated with sustained increases in blood pressure (BP) in some patients. Regular BP monitoring is recommended. Abrupt discontinuation or dose reduction has been associated with discontinuation symptoms. Patients should be counseled on possible discontinuation symptoms and monitored while discontinuing the drug; the dose should be tapered gradually.
"The most common adverse events reported in EFFEXOR XR short-term placebo-controlled depression trials and EFFEXOR XR short-term placebo-controlled depression, generalized anxiety disorder (GAD), and/or social anxiety disorder trials (incidence >10% and >2x that of placebo) were anorexia, asthenia, constipation, dizziness, dry mouth, ejaculation problems, impotence, insomnia, nausea, nervousness, somnolence, and sweating...."
poster:dancingstar
thread:13781
URL: http://www.dr-bob.org/babble/20050103/msgs/438187.html